Patient-derived tumor xenograft, PDX, is a tissue proliferated in immunodeficient mice to which tumor tissue fragments excised from a patient were transplanted. This tissue allows us to study the properties of human tumor cells under environmental conditions similar to the human body as opposed to in culture. The PDX model is considered an extremely useful tool for discovering and developing anticancer agents.
In the Fukushima Translational Research Project (Fukushima Project), PDX is evaluated by histopathological examination and comprehensive gene expression analysis. If it is confirmed to retain the characteristics of the original tumor tissue and meet the criteria, it is eligible for an established line and named F-PDX (Fukushima PDX). The catalog lists a total of 164 lines (F-PDX list Ver.5) of F-PDX established so far in the Fukushima Project, covering a wide variety of solid tumors such as ovarian, lung, and colorectal cancers, as well as hematopoietic tumors such as leukemia.
|Human multiple myeloma (MM) xenograft model|